Evommune, Inc.
EVMN NYSE· Pharmaceutical Preparations
Last close · Oct 26, 2026
$5.13
KIRA · Stoqly’s AI analyst, in plain words
- Evommune, Inc. had $13.0M of revenue in fiscal 2025, up 85.7% on the year before.
- Its operating margin was −623.6%, up 376.6 pts: of every 100 in sales, about −624 is left after running the business.
- Evommune, Inc. lost $68.9M in fiscal 2025.
- Free cash flow was −$76.7M in fiscal 2025, −589.8% of revenue.
Market cap
$185M
P/E
0.9x
Revenue
$13.0M
Net income
−$68.9M
Free cash flow
−$76.7M
Operating margin
−623.6%
Evommune, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+85.7%
Yes. Sales grew 85.7% last year.
Does it make a profit?
−529.8%
No. It lost money last year.
Does profit turn into cash?
−589.8%
No. It spent more cash than it brought in.
How healthy are the accounts?
2 / 7
Weak. It passes 2 of 7 health tests.
How is the share priced?
0.9x
One share costs 0.9 times its yearly profit per share.
What Evommune, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 5, 2026
- Legal name
- Evommune, Inc.
- CIK
- 0002044725
Evommune, Inc. · EVMN
Results and finances
The last 2 fiscal years. Amounts in USD.
| Fiscal year | FY24 | FY25 |
|---|---|---|
| Sales and profit | ||
| Revenue | $7.0M | $13.0M |
| Revenue growth | — | 85.7% |
| Operating margin | −1,000.2% | −623.6% |
| Net income | −$66.8M | −$68.9M |
| Net margin | −954.4% | −529.8% |
| Diluted EPS | −$45.29 | −$11.22 |
| Cash | ||
| Cash from operations | −$58.2M | −$76.4M |
| Capital expenditure | $0.1M | $0.2M |
| Free cash flow | −$58.3M | −$76.7M |
| FCF margin | −832.6% | −589.8% |
| Share count change | — | 306.9% |
| Debt and strength | ||
| Cash and short-term investments | $72.0M | $149M |
| Shareholders' equity | −$144M | $206M |
| Current ratio | 2.6x | 8.6x |
| Returns and quality | ||
| Return on equity | — | −224.6% |
| Return on tangible equity | — | −33.5% |
| Piotroski F-score | — | 2 |
| Altman Z'' | −14.1 | 9.5 |
Insiders bought, 12 months
$45.2M
5 insiders
Insiders sold, 12 months
$2.3M
6 insiders
Of sales under plans
100%
$2.3M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Evommune, Inc. · EVMN
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $5.13 a share, the company is worth $185M: 0.9 times its earnings of the last four quarters.
Source: SEC EDGAR XBRL filings (CIK 0002044725). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.